Shattuck Labs, Inc. Company profile
About Shattuck Labs Inc
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of dual-sided fusion proteins. The Company has created an approach to immune modulation by designing biologics with structural characteristics. Compounds derived from its Agonist Redirected Checkpoint (ARC) platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the cluster of differentiation 47/signal regulatory protein alpha (CD47/SIRPa) checkpoint interaction to restore an anti-tumor immune response and to activate the cluster of differentiation 40 (CD40) costimulatory receptor to bolster an immune response. The Company's second product candidate, SL-279252, is designed to simultaneously inhibit the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction and activate the OX40 receptor.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Shattuck Labs Inc revenues increased from $9.9M to $30M. Net loss increased 23% to $45M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 47% to $54.4M (expense), General and administrative - Balancing increase of 79% to $15.5M (expense).
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)